In early 2022, the AACU joined more than 20 other organizations in supporting biomarker testing legislation introduced in Ohio (HB 608). This legislation continues to move forward, and passed the House Health Committee this week with only one vote in opposition. Bills like this are on AACU’s radar because they would ensure that Ohioans covered by state-regulated insurance plans, including Medicaid, have coverage for biomarker testing when medically appropriate. Improving access to biomarker testing and thereby access to targeted therapies is also an important strategy to reduce health disparities and improve outcomes for cancer patients.
The AACU submitted written testimony on behalf of urologists and patients in Ohio, and we will continue to update our members as this progresses through the legislature.
More Recent AACU News
The Silent Epidemic: AACU and Man vs Prostate Call for a National Pivot Toward Bladder Health
The American Association of Clinical Urology (AACU), in a strategic partnership with Wayne Kuang, MD, and the Man vs Prostate initiative, is calling for immediate national action to address what we have termed the "silent epidemic" of male bladder health. Although the...
AACU Supports the Legislative Spirt of the Break Up Medicine Act
For much of the past decade, the structure of the healthcare marketplace has shifted toward increasing vertical integration. Insurers, pharmacy benefit managers, provider groups, and supply chain entities have become more closely aligned under common ownership...
AACU Supports H.R. 7602 which Seeks to Establish an Office of Men’s Health within the Department of Health and Human Services
The American Association of Clinical Urology (AACU) publicly supports H.R. 7602 titled “State of Men’s Health Act” sponsored by Representative Troy Carter, (D-LA) and Representative Greg Murphy (R-NC).